Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AptarGroup ( (ATR) ) has issued an announcement.
On March 16, 2026, AptarGroup announced that President and CEO Stephan Tanda will retire from his executive roles effective Sept. 1, 2026, with Aptar Pharma president Gael Touya appointed as his successor and expected to join the board at that time. Tanda will remain on the board and serve as a strategic adviser through Dec. 31, 2026, under a separate letter agreement that preserves his 2025-level pay and incentive opportunities during the transition period.
Touya’s new employment agreement runs initially through Dec. 31, 2028, with automatic one-year extensions, and provides for a $1.06 million base salary, enhanced annual and long-term incentive opportunities, relocation support, and detailed severance and change-in-control protections. As part of the leadership transition, AptarGroup also granted sizable retention equity awards to Chief Financial Officer Vanessa Kanu and Aptar Closures president Hedi Tlili, underscoring the board’s focus on continuity and stability across the senior management team.
The most recent analyst rating on (ATR) stock is a Hold with a $147.00 price target. To see the full list of analyst forecasts on AptarGroup stock, see the ATR Stock Forecast page.
Spark’s Take on ATR Stock
According to Spark, TipRanks’ AI Analyst, ATR is a Outperform.
The score is driven primarily by strong underlying financial performance (steady growth, solid margins, and manageable leverage). This is supported by generally positive near-term technical momentum, while a mid-range valuation and a balanced earnings-call outlook—strong pipeline and buybacks offset by near-term margin/EPS headwinds—keep the overall score in the mid-70s.
To see Spark’s full report on ATR stock, click here.
More about AptarGroup
AptarGroup, Inc. is a global provider of dispensing, drug delivery and active material science solutions serving the pharmaceutical, beauty, personal care, food and beverage markets. The company operates through segments including Aptar Pharma and Aptar Closures, focusing on innovative packaging and delivery systems for regulated and consumer end-markets worldwide.
Average Trading Volume: 511,176
Technical Sentiment Signal: Hold
Current Market Cap: $8.31B
See more insights into ATR stock on TipRanks’ Stock Analysis page.